Increased amyloid-β levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet

Journal of Nutrition, Health and Aging

Volumn 6, Issue 5, 2002, Pages 315-319

  Levin Allerhand, J A ^b   Lominska, C E ^b   Smith, J D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; BRAIN BLOOD FLOW; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; GENETIC RISK; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

EID: 0036963532     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Smith JD. Mouse models of atherosclerosis. Lab Anim Sci. 1998;48(6):573-9.
2. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology. 1995;45(6):1092-6.
3. Romas SN, Tang MX, Berglund L, Mayeux R. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology, 1999;53(3):517-21.
4. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17(1):14-20.
5. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356(9242):1627-31.
6. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57(10):1439-43.
7. Haley RW, Dietschy JM. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? Arch Neurol. 2000;57(10):1410-2.
8. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998:95(11):6460-4.
9. Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 1996;271(8):4436-40.
10. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98(10):5856-61.
11. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci U S A. 2001;98(10):5815-20.
12. Howland DS, Trusko SP, Savage MJ, et al. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem. 1998;273(26):16576-82.
13. Refolo LM, Pappolla MA, Malester B. et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7(4):321-31.
14. Borchelt DR, Davis J, Fischer M, et al. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal. 1996;13(6):159-63.
15. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol. 2001;12(2):105-12.
16. Eckert GP, Kirsch C, Mueller WE. Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice. Neuroreport. 2001;12(5):883-7.
17. Giem P, Beeson WL, Fraser GE. The incidence of dementia and intake of animal products: preliminary findings from the Adventist Health Study. Neuroepidemiology. 1993;12(1):28-36.2
18. Petot G, Cook T, Chen C, et al. A high fat diet during adulthood increases risk for Alzheimer's disease for those with the ApoE-E4 allele. Neurobiology of Aging. 2000;21(1S):S246.
19. McGowan E, Sanders S, Iwatsubo T, et al. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis. 1999;6(4):231-44.
20. Borchelt DR, Ratovitski T, van Lare J, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19(4):939-45.
21. Vesselinovitch D, Wissler RW. Experimental production of atherosclerosis in mice. Effects of atherogenic and high-fat diets on vascular changes in chronically and acutely irradiated mice. J Atheroscler Res. 1968;8(3):497-523.
22. Morrisett, JD, Kim, H-S, Patsch, JR, Datta, SK, Trentin, JJ. Genetic susceptibility and resistance to diet-induced atherosclerosis and hyperlipoproteinemia. Arteriosclerosis 1982;2:312-324.
23. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis. 1985;57(1):65-73.
24. Liao F, Andalibi A, deBeer FC, Fogelman AM, Lusis AJ. Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. J Clin Invest. 1993;91(6):2572-9.
25. Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71(2):343-53.